

Cover Figure

The cover image shows the structure of the myristate pocket in the ABL (ABL1) kinase domain (blue) in complex with myristate (yellow). This figure is taken from the editorial by Oliver Hantschel on page 157.

Hematology News

155 **A fly's view of the hematopoietic niche**
Jan Cools

156 **Using the hemoglobin switch for the treatment of sickle cell disease**
Jan Cools

Editorials and Perspectives

157 **Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance**
Oliver Hantschel

Review Article

Hematopoiesis & Hematopoietic Stem Cells

160 **MicroRNAs are shaping the hematopoietic landscape**
Ute Bissels, Andreas Bosio, and Wolfgang Wagner

Original Articles and Brief Reports

Hematopoiesis & Hematopoietic Stem Cells

168 **HOXC4 homeoprotein efficiently expands human hematopoietic stem cells and triggers similar molecular alterations as HOXB4**
Céline Auvray, Andrée Delahaye, Françoise Pflumio, Rima Haddad, Sophie Amsellem, Ayda Miri-Nezhad, Loïc Broix, Azzedine Yacia, Frédérique Bulle, Serge Fichelson, and Isabelle Vigon

179 **The composition of the mesenchymal stromal cell compartment in human bone marrow changes during development and aging**
Marijke W. Maijenburg, Marion Kleijer, Kim Vermeul, Erik P.J. Mul, Floris P.J. van Alphen, C. Ellen van der Schoot, and Carlijn Voermans

Cytogenetics and Molecular Genetics

184 **t(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34**
Mathijs Baens, Julio Finalet Ferreiro, Thomas Tousseyn, Helena Urbankova, Lucienne Michaux, Laurence de Leval, Daan Dierickx, Pascal Wolter, Xavier Sagaert, Peter Vandenberghe, Christiane De Wolf-Peeters, and Iwona Wlodarska

Iron Metabolism & Its Disorders

189 **Hemojuvelin is essential for transferrin-dependent and transferrin-independent hepcidin expression in mice**
Thomas B. Bartnikas and Mark D. Fleming

Red Cell Disorders

193 **Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL^{R200W} mutation (Chuvash polycythemia)**
Craig A. Sable, Zakari Y. Aliyu, Niti Dham, Mehdi Nourae, Vandana Sachdev, Stanislav Sidenko, Galina Y. Miasnikova, Lydia A. Polyakova, Adelina I. Sergueeva, Daniel J. Okhotin, Vladimir Bushuev, Alan T. Remaley, Xiaomei Niu, Oswaldo L. Castro, Mark T. Gladwin, Gregory J. Kato, Josef T. Prchal, and Victor R. Gordeuk

201 **Association between hemolysis and albuminuria in adults with sickle cell anemia**
Thomas G. Day, Emma R. Drasar, Tony Fulford, Claire C. Sharpe, and Swee Lay Thein

Myelodysplastic Syndromes

206 **Therapy-related myeloid neoplasms following treatment with radioiodine**
Thomas Schroeder, Andrea Kuedgen, Sabine Kayser, Nicolaus Kröger, Friederike Bräulke, Uwe Platzbecker, Viola Klärner, Fabian Zohren, Detlef Haase, Michael Stadler, Richard Schlenk, Akos G. Czibere, Ingmar Bruns, Roland Fenk, Norbert Gattermann, Rainer Haas, Guido Kobbe, and Ulrich Germing

213 **Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies**
Lionel Adès, Fabien Le Bras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, François Dreyfus, Virginie Eclache, Jacques Delaunay, Didier Bouscary, Sorin Visanica, Pascal Turlure, Agnès Guerci Bresler, Marie-Paule Cabrol, Anne Banos, Michel Blanc, Norbert Vey, Alain Delmer, Eric Wattel, Sylvie Chevret, and Pierre Fenaux



Official Organ of the
European Hematology Association

Chronic Myeloid Leukemia

- 219** **CD34⁺/CD38⁻ stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin**
Harald Herrmann, Sabine Cerny-Reiterer, Karoline V. Gleixner, Katharina Blatt, Susanne Herndlhofer, Werner Rabitsch, Eva Jäger, Gerlinde Mitterbauer-Hohendanner, Berthold Streubel, Edgar Selzer, Ilse Schwarzwinger, Wolfgang R. Sperr, and Peter Valent

Acute Myeloid Leukemia

- 227** **Results of the APLM3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia**
Harry Iland, Ken Bradstock, John Seymour, Mark Hertzberg, Andrew Grigg, Kerry Taylor, John Catalano, Paul Cannell, Noemi Horvath, Sandra Deveridge, Peter Browett, Tim Brighton, Li Chong, Francisca Springall, Juliet Ayling, Alberto Catalano, Shane Supple, Marnie Collins, Juliana Di Iulio, and John Reynolds, for the Australasian Leukaemia and Lymphoma Group
- 235** **Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients**
Aref Al-Kali, Sergej Konoplev, Erpei Lin, Tapan Kadia, Stefan Faderl, Farhad Ravandi, Mohamad Ayoubi, Mark Brandt, Jorge E. Cortes, Hagop Kantarjian, and Gautam Borihakur
- 241** **Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC**
Pierre Hirsch, Ruoping Tang, Christophe Marzac, Jean-Yves Perrot, Fanny Fava, Chantal Bernard, Dorota Jeziorowska, Jean Pierre Marie, and Ollivier Legrand
- 246** **Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia**
Isabella Fried, Claudia Bodner, Monika M. Pichler, Karin Lind, Christine Beham-Schmid, Franz Quehenberger, Wolfgang R. Sperr, Werner Linkesch, Heinz Sill, and Albert Wölfler

Acute Lymphoblastic Leukemia

- 251** **p185^{BCR/ABL} has a lower sensitivity than p210^{BCR/ABL} to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia**
Afsar A. Mian, Anna Metodieva, Yousef Najajreh, Oliver G. Ottmann, Jamal Mahajna, and Martin Ruthardt

- 258** **Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements**
Irene Homminga, Maartje J. Vuerhard, Anton W. Langerak, Jessica Buijs-Gladdines, Rob Pieters, and Jules P.P. Meijerink

Hodgkin's Lymphoma

- 262** **Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma**
Luis F. Porrata, Kay Ristow, Joseph P. Colgan, Thomas M. Habermann, Thomas E. Witzig, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Grzegorz S. Nowakowski, Carrie Thompson, and Svetomir N. Markovic

Non-Hodgkin's Lymphomas

- 270** **In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior**
Alejandra Carvajal-Cuenca, Luz F. Sua, Nhora M. Silva, Stefania Pittaluga, Cristina Royo, Joo Y. Song, Rachel L. Sargent, Blanca Espinet, Fina Climent, Samuel A. Jacobs, Jan Delabie, Kikkeri N. Naresh, Adam Bagg, Pierre Brousset, Roger A. Warnke, Sergi Serrano, Nancy Lee Harris, Steven H. Swerdlow, Elaine S. Jaffe, and Elías Campo

Chronic Lymphocytic Leukemia

- 279** **CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study**
Giovanni Del Poeta, Maria Ilaria Del Principe, Antonella Zucchetto, Fabrizio Luciano, Francesco Buccisano, Francesca Maria Rossi, Antonio Bruno, Annalisa Biagi, Pietro Bulian, Luca Maurillo, Benedetta Neri, Riccardo Bomben, Cristina Simotti, Angela Maria Coletta, Michele Dal Bo, Paolo de Fabritiis, Adriano Venditti, Valter Gattei and Sergio Amadori
- 288** **Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells**
Mariam Hammadi, Pierre Youinou, Adrian Tempescul, Gabriel Tobón, Christian Berthou, Anne Bordron, and Jacques-Olivier Pers



Official Organ of the
European Hematology Association

Disorders of Coagulation

297 Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura
Rahel Froehlich-Zahnd, James N. George, Sara K. Vesely, Deirdra R. Terrell, Khatira Aboulfatova, Jing-Fei Dong, Brenda M. Luken, Jan Voorberg, Ulrich Budde, Imela Sulzer, Bernhard Lämmle, and Johanna A. Kremer Hovinga

304 Heterogeneous lengths of copy number mutations in human coagulopathy revealed by genome-wide high-density SNP array
Hee-Jin Kim, Duk-Kyung Kim, Ki-Young Yoo, Chur-Woo You, Jong-Ha Yoo, Ki-O Lee, In-Ae Park, Hae-Sun Choung, Hee-Jung Kim, Min-Jung Song, and Sun-Hee Kim

Stem Cell Transplantation

310 Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study – a prospective clinical trial by the Grupo Español de Linfomas/ Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Anna Sureda, Carme Canals, Reyes Arranz, Dolores Caballero, Josep Maria Ribera, Mats Brune, Jacob Passweg, Rodrigo Martino, David Valcárcel, Joan Besalduch, Rafael Duarte, Angel León, Maria Jesus Pascual, Ana Garcia-Noblejas, Lucía López Corral, Bianca Xicoy, Jordi Sierra, and Norbert Schmitz

Letters to the Editor

318 A novel compound heterozygous HAX1 mutation in a Chinese patient with severe congenital neutropenia and chronic myelomonocytic leukemia transformation but without neurodevelopmental abnormalities
Sheng-Li Xue, Jin-Li Li, Jing-Ying Zou, Jian Su, Su-Ning Chen, and De-Pei Wu

320 POEMS syndrome with severe neurological damage clinically recovered with lenalidomide
José F. Tomás, Pilar Giraldo, Ramón Lecumberri, and Sara Nistal

Online-Only Articles

e2 MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine
Massimo Breccia, Adriano Salaroli, Giuseppina Loglisci, Paola Finsinger, Alessandra Serrao, and Giuliana Alimena

e3 Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the GC subgroup and younger patients in the non-GC subgroup
Ulf Thunberg, Gunilla Enblad, and Mattias Berglund

e4 Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup (Reply)
Fabrice Jardin

Continuing Medical Education

Hypocellular acute myeloid leukemia

Lenalidomide treatment for lower risk myelodysplastic syndromes

All-trans-retinoic acid and idarubicin in the initial therapy of acute promyelocytic leukemia

Prognostic role of CD69 in chronic lymphocytic leukemia